ABPI suspends Novo Nordisk membership
Pharmaceutical company Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years.
Pharmaceutical company Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years.
New clinical data has indicated that Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by pharmaceutical company Novo Nordisk, is effective for sustained weight loss.
An Expert Clinic session focusing on obesity will take place at the Aesthetics Conference and Exhibition (ACE) 2019 on Saturday March 2 from 3.30pm.